Ketoprofen spray – maximal therapeutic effectiveness defined by tissue penetration and treatment tolerability | Medycyna Faktow (J EBM)

PDF (Język Polski)

Published: Mar 1, 2026

DOI: https://doi.org/10.24292/01.MF.0425.09

Keywords:

ketoprofen, topical non-steroidal anti-inflammatory drugs, spray formulation, ankle sprain, soft tissue injuries, acute pain, topical therapy

Tomasz Blicharski

Klinika Rehabilitacji, Uniwersytet Medyczny w Lublinie

Abstract

Acute soft tissue injuries, such as grade I and II ankle sprains, are among the most common causes of musculoskeletal pain encountered by primary care physicians and orthopedic specialists. Effective treatment should provide rapid relief of pain and swelling while enabling an early return to full function, with a high level of safety. Ketoprofen is a non-steroidal anti-inflammatory drug with proven analgesic and anti-inflammatory efficacy. Topical administration allows a high concentration of the drug to be delivered directly to the site of injury, thereby minimizing the risk of systemic adverse effects. Clinical studies indicate that topical ketoprofen leads to effective reduction of pain and swelling in acute soft tissue injuries. An important factor influencing therapeutic effectiveness is the drug formulation. The spray formulation enables improved penetration of ketoprofen into inflamed tissues. Clinical studies in patients with ankle sprains have demonstrated faster and greater reductions in pain and swelling, as well as a significant improvement in function, compared with orally administered ketoprofen. Topical ketoprofen is characterized by good tolerability and a low risk of adverse effects typically associated with oral non-steroidal anti-inflammatory drugs. Ketoprofen in spray form represents a rational therapeutic option in the management of acute soft tissue injuries and can be effectively used in outpatient settings.

How to Cite

Blicharski, T. (2026). Ketoprofen spray – maximal therapeutic effectiveness defined by tissue penetration and treatment tolerability. Medycyna Faktow (J EBM), 19(4(69), 543-548. https://doi.org/10.24292/01.MF.0425.09

Issue

Vol 19 No 4(69) (2025)

Section

Articles

Copyright by Medical Education. All rights reserved.

References

1. Doherty C, Delahunt E, Caulfield B et al. The incidence and prevalence of ankle sprain injury: a systematic review and meta-analysis of prospective epidemiological studies. Sports Med. 2014; 44(1): 123-40. http://doi.org/10.1007/s40279-013-0102-5.
2. Fong DT, Hong Y, Chan LK et al. A systematic review on ankle injury and ankle sprain in sports. Sports Med. 2007; 37(1): 73-94. http://doi.org/10.2165/00007256-200737010-00006.
3. Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs. Ther Clin Risk Manag. 2015; 11: 1061-75. http://doi.org/10.2147/TCRM.S79135.
4. Derry S, Moore RA, Gaskell H et al. Topical NSAIDs for acute musculoskeletal pain in adults. Cochrane Database Syst Rev. 2015; 2015(6): CD007402. http://doi.org/10.1002/14651858.CD007402.pub3.
5. Rainsford KD. Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology. 2009; 17(6): 275-342. http://doi.org/10.1007/s10787-009-0016-x .
6. Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015; 8: 105-18. http://doi.org/10.2147/JPR.S75160.
7. Vinciguerra G, Belcaro G, Cesarone MR et al. Management of uncomplicated ankle sprains with topical or oral ketoprofen treatment. A registry study. Minerva Cardioangiol. 2008; 56(5 Suppl): 47-53.
8. Rother M, Conaghan PG. A randomized, double-blind, phase III trial in moderate osteoarthritis knee pain comparing topical ketoprofen gel with ketoprofen-free gel. J Rheumatol. 2013; 40(10): 1742-8. http://doi.org/10.3899/jrheum.130192.
9. Rainsford KD. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med. 1999; 107(6A): 27S-35S. http://doi.org/10.1016/s0002-9343(99)00365-4.
10. Esparza F, Cobián C, Jiménez JF et al.; Working group for the acute pain study of SETRADE. Topical ketoprofen TDS patch versus diclofenac gel: efficacy and tolerability in benign sport related soft-tissue injuries. Br J Sports Med. 2007; 41(3): 134-9.
11. Lanas A, Ferrandez A. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention. Chin J Dig Dis. 2006; 7(3): 127-33. http://doi.org/10.1111/j.1443-9573.2006.00257.x.
12. Singh P, Roberts MS. Skin permeability and local tissue concentrations of nonsteroidal anti-inflammatory drugs after topical application. J Pharmacol Exp Ther. 1994; 268(1): 144-51.
13. Brune K, Hinz B. The discovery and development of antiinflammatory drugs. Arthritis Rheum. 2004; 50(8): 2391-9. http://doi.org/10.1002/art.20424.
14. Goodwin DA, Fuhrman LC. Enhancement of skin penetration of nonsteroidal anti-inflammatory drugs from extemporaneously compounded topical-gel formulations. Int J Pharm Compd. 1999; 3(6): 496-500.
15. Mason L, Moore RA, Edwards JE et al. Topical NSAIDs for acute pain: a meta-analysis. BMC Fam Pract. 2004; 5: 10. http://doi.org/10.1186/1471-2296-5-10.
16. van den Bekerom MPJ, Sjer A, Somford MP et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for treating acute ankle sprains in adults: benefits outweigh adverse events. Knee Surg Sports Traumatol Arthrosc. 2015; 23(8): 2390-99. http://doi.org/10.1007/s00167-014-2851-6.
17. Bally M, Dendukuri N, Rich B et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ. 2017; 357: j1909. http://doi.org/10.1136/bmj.j1909.